Clinical infrastructure specialist Feedback plc (AIM: FDBK) announced on Wednesday that it is collaborating with Vertex In Healthcare, a clinical IT firm with operations in the UK, UAE and South Africa. This agreement aims to combine technologies and resell products, driving commercial opportunities in multiple markets. The collaboration outlines the terms for future definitive commercial agreements.
Vertex, a registered UK reseller of the MedDream medical image viewer by UAB Softneta, brings regulatory approvals (FDA Cleared and CE Marked) across the USA, Middle East and Europe. Feedback will integrate the MedDream viewer into Bleepa, enhancing its teleradiology offerings and enabling direct sales to Radiologists for primary diagnostic reporting services. This integration will expand Feedback's reach into key markets like the USA and the Middle East, while maintaining a primary focus on India.
The partnership allows Feedback and Vertex to resell each other's products, facilitating rapid and cost-effective expansion into new territories. Bleepa's integration into Vertex's solutions will help increase market share across various customer segments.
As part of the agreement, Vertex will license Feedback's legacy picture archiving communication system, Cadran PACS, with the MedDream Viewer. This will help build a PACS proposition initially targeted at South Africa and other international markets, including the UK, generating licensing royalties for Feedback.
Feedback's products, Bleepa and CareLocker, enhance clinician access to patient data and facilitate remote clinical team collaboration. Bleepa displays clinical results from CareLocker, enabling secure, auditable dialogue among clinicians. This model supports flexibility for clinicians and seamless patient movement between providers.
Feedback's SaaS-based model targets growth across the NHS, veterinary markets and private healthcare providers, anticipating increased revenue visibility as its customer base expands.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA